PROCEPT BioRobotics Corp. to Present at the 41st Annual J.P. Morgan Healthcare Conference
15 12월 2022 - 6:05AM
PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical
robotics company focused on advancing patient care by developing
transformative solutions in urology, today announced that members
of management will present at the upcoming 41st Annual J.P. Morgan
Healthcare Conference. Management is scheduled to present on
Tuesday, January 10 at 9:45 a.m. Pacific Time. A live webcast of
the event, as well as an archived recording, will be available on
the “Investors” section of the company’s website at:
https://ir.procept-biorobotics.com. The webcasts will be archived
and available for replay for at least 90 days after the event.
About PROCEPT BioRobotics CorporationPROCEPT
BioRobotics is a surgical robotics company focused on advancing
patient care by developing transformative solutions in urology.
PROCEPT BioRobotics develops, manufactures and sells the AquaBeam
Robotic System, an advanced, image-guided, surgical robotic system
for use in minimally-invasive urologic surgery with an initial
focus on treating benign prostatic hyperplasia, or BPH. BPH is the
most common prostate disease and impacts approximately 40 million
men in the United States. PROCEPT designed Aquablation therapy to
deliver effective, safe and durable outcomes for males suffering
from lower urinary tract symptoms, or LUTS, due to BPH that are
independent of prostate size and shape or surgeon experience. The
Company has developed a significant and growing body of clinical
evidence, which includes nine clinical studies and over 100
peer-reviewed publications, supporting the benefits and clinical
advantages of Aquablation therapy.
Investor Contact:Matt Bacso, CFAVP, Investor
Relations and Business
Operationsm.bacso@PROCEPT-BioRobotics.com
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024